This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Reaxys Medicinal Chemistry Now Offers The World's Largest Medicinal Chemistry Database

AMSTERDAM, May 12, 2014 /PRNewswire/ --

Reaxys    Medicinal    Chemistry    enables    scientists    to    explore    new    drug    candidates    through    a    comprehensive    database    with    new    search    features,    refined    user-interface    and    integration    with    Reaxys

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Reaxys Medicinal Chemistry offers the world's largest medicinal chemistry database. Reaxys Medicinal Chemistry enables researchers to quickly and confidently identify the most promising compounds to take forward in the drug discovery process by covering critical areas for medicinal chemistry research, including in vivo animal studies, in vitro efficacy, drug pharmacokinetics and toxicity data.

The Reaxys Medicinal Chemistry database contains 25 million bioactivity data points, making it the largest such dataset, with corresponding bioassays on 5.1 million unique substances compiled from 320,000 medicinal chemistry publications and patents, fully indexed and normalized.

Users who subscribe to both Reaxys and Reaxys Medicinal Chemistry will have a comprehensive view of the most relevant bioactivity data and be able to explore the structures and physiochemical properties of other known compounds, via a single integrated interface. With access to the automatic synthesis pathway generator, users can immediately start to work on selected substances. This will facilitate workflows from lead identification to compound synthesis and enable scientists to generate new drug ideas by exploring the chemical space of new compounds.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $37.40 3.90%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs